TC-1698
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem (CID) | 10130417 |
| ChemSpider |
8305933  N |
| ChEMBL |
CHEMBL2151442 N |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.295 |
| 3D model (Jmol) | Interactive image |
| |
| |
N Y (what is this?) (verify) | |
TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1] It has neuroprotective effects in animal studies,[2] and has been used as a lead compound to find further potent derivatives.[3]
References
- ↑ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
- ↑ Marrero, M.; Papke, R.; Bhatti, B.; Shaw, S.; Bencherif, M. (2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo3.2.2nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 16–27. doi:10.1124/jpet.103.061655. PMID 14722323.
- ↑ Bhatti, B.; Strachan, J.; Breining, S.; Miller, C.; Tahiri, P.; Crooks, P.; Deo, N.; Day, C.; Caldwell, W. (2008). "Synthesis of 2-(Pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(Pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(Pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a Class of Potent Nicotinic Acetylcholine Receptor-Ligands". The Journal of Organic Chemistry. 73 (9): 3497–507. doi:10.1021/jo800028q. PMID 18363376.
This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.